Shattuck Labs, Inc. (STTK) Stock

Shattuck Labs, Inc. (STTK) is a Healthcare stock trading at $7.54 (as of 2026-08-21), with a market capitalization of $578.55M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Shattuck Labs, Inc. is a clinical-stage biotechnology company developing therapeutics for cancer and autoimmune disease. Its clinical-stage pipeline includes SL-172154 for ovarian, fallopian tube, and peritoneal cancers and SL-279252 for advanced solid tumors and lymphoma, with development based in the United States.

Understand Shattuck Labs, Inc.: how it makes money

Shattuck Labs is a clinical-stage biotech developing cancer therapeutics, including SL-172154 and SL-279252, and it makes money, when available, through collaboration and licensing revenue.

Because Shattuck Labs is a clinical-stage company, its path to profitability depends on clinical development progress (response and survival outcomes) turning into future collaboration or licensing income, yet its reported collaboration and licensing revenue is currently 0.0.

Revenue by segment (latest quarter)
Collab$0.0B
Lic&Collab$0.0B

Business quality (Weak): Early clinical efficacy signals are reported for SL-172154 in Phase 1 cohorts, but the business shows no collaboration or licensing revenue in the latest quarter and has a deeply negative operating margin.

Bull case

  • Reported response in Phase 1B combination cohorts: Overall Response Rate in Phase 1B Combination Cohort is 67 percent, and Complete Remission Rate is 33 percent.
  • Survival metrics are also being tracked: Current Median Overall Survival is 15.6 (ratio), with different values reported for key biomarker subsets.

Bear case

  • No reported collaboration or licensing revenue yet: Collaboration Revenue is 0.0, and Licensing and Collaboration Revenue is 0.0 for the latest reported period.
  • Profitability is not demonstrated: The operating margin is -1071.6 for the latest reported period, indicating substantial operating losses relative to revenue.
Valuation — source: SEC EDGAR (first-party)
Price$7.54
Market Cap$578.55M
Price / Book2.74
Price / Sales578.55
FCF Yield-9.5%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$1.00M
Net Margin-4880.9%
Revenue Growth (YoY)-82.5%
EPS Growth (YoY)-53.0%
FCF Growth (YoY)-34.0%
Financial Health — source: SEC EDGAR
Altman Z-Score30.03 (safe)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderPIPER SANDLER & CO. ($253.77M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOTaylor H. Schreiber
Employees44
CountryUS
IPO Date2020-10-09

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Arvinas, Inc. (ARVN)
  • Verastem, Inc. (VSTM)
  • Altimmune, Inc. (ALT)
  • Aquestive Therapeutics, Inc. (AQST)
  • Evolus, Inc. (EOLS)
  • ARS Pharmaceuticals, Inc. (SPRY)
  • Ovid Therapeutics Inc. (OVID)
  • Sagimet Biosciences Inc. (SGMT)
STTK earnings history · STTK institutional & insider holders · STTK KPIs & operating metrics · STTK financials · STTK investor presentations & press releases · STTK SEC filings · STTK peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.